Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial

@article{Mok2007RisedronateFP,
  title={Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial},
  author={Chi Chiu Mok and Ka Hang Tong and Chi Hung To and Yui Pong Siu and Kwok Man Ma},
  journal={Osteoporosis International},
  year={2007},
  volume={19},
  pages={357-364}
}
SummaryThis 6-month randomized double-blind placebo-controlled trial shows that risedronate is well tolerated and effective in improving lumbar spine BMD and reducing loss of BMD at the hips in patients receiving high-dose prednisolone.IntroductionBisphosphonates have proven benefits in patients receiving chronic low-dose glucocorticoids. However, whether they are effective in preventing bone mineral density (BMD) loss during periods of high-dose glucocorticoid treatment is unclear. The… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis

  • Therapeutic advances in musculoskeletal disease
  • 2010
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

a randomized controlled trial comparing calcitriol and hormonal replacement therapy

AW Kung, TM Chan, therapy Lau CS et al Osteopenia in young hypogonadal women steroid
  • Rheumatology (Oxford) 38:1239–1244 Osteoporos Int
  • 2008
VIEW 1 EXCERPT

a randomized, double-blind, placebo-controlled trial

S Adami, K Pavelka, NSAIDs Cline GA et al Upper gastrointestinal tract safety taking
  • Mayo Clin Proc 80:1278–1285 364 Osteoporos Int
  • 2008
VIEW 1 EXCERPT

Osteoporosis associated with excess glucocorticoids.

  • Endocrinology and metabolism clinics of North America
  • 2005
VIEW 1 EXCERPT